Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neoplasms 1Neoplasm Metastasis 1Digestive System Neoplasms 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1Adenocarcinoma 1

Interventions

Cisplatin 62Carboplatin 52Paclitaxel 49Radiotherapy 47Docetaxel 42Gemcitabine 38Cyclophosphamide 36Rituximab 33Capecitabine 28Fluorouracil 27Dexamethasone 27Doxorubicin 26Prednisone 21Bevacizumab 20Pemetrexed 19Oxaliplatin 18Leucovorin 18pembrolizumab 17Vincristine 17Etoposide 17Cytarabine 15Imatinib Mesylate 14Drug Therapy 14Irinotecan 13Filgrastim 13Zoledronic Acid 12Trastuzumab 12Radiosurgery 12Erlotinib Hydrochloride 12Goserelin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Terminated × NUC-1031 × Clear all
NCT04163900 2023-05-24

Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer

NuCana plc

Phase 3 Terminated
773 enrolled 15 charts
Gastrointestinal

Adenocarcinoma, Biliary Tract Neoplasms, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡